A Randomized Phase II Study Comparing 2 Stereotactic Body Radiation Therapy (SBRT) Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. It is not yet known which regimen of stereotactic body radiation therapy is more effective in treating patients with non-small cell lung cancer. PURPOSE: This randomized phase II trial is studying the side effects of two radiation therapy regimens and to see how well they work in treating patients with stage I non-small cell lung cancer.
Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.
- Joseph Shrager
- Maximilian Diehn, MD, PhD
- A. Dimitrios Colevas
- Billy W. Loo, Jr., MD, PhD, DABR
- Peter G Maxim
- Heather Wakelee, MD
- radiation : Multiple-fraction stereotactic body radiation therapy (SBRT)
- radiation : Single-fraction stereotactic body radiation therapy (SBRT)
Phase: Phase 2
Ages Eligible For Study: